U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows

BioLife Solutions

Market Cap: US$1.0b

Develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.

Vertex Pharmaceuticals

Market Cap: US$120.6b

A biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).

Repligen

Market Cap: US$6.7b

A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.

Ligand Pharmaceuticals

Market Cap: US$2.5b

A biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.

Mesa Laboratories

Market Cap: US$434.8m

Develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.

Niagen Bioscience

Market Cap: US$907.8m

Operates as a bioscience company engages in developing healthy aging products.

Eli Lilly

Market Cap: US$709.0b

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.

Natera

Market Cap: US$20.3b

A diagnostics company, provides molecular testing services worldwide.

Bruker

Market Cap: US$6.3b

Develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally.